Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

Next Previous
Trial Profile

A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NKX 019 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Myositis; Rheumatoid arthritis; Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms Ntrust-2
  • Sponsors Nkarta Therapeutics

Most Recent Events

  • 15 Apr 2026 According to a Nkarta Therapeutics media release, Outpatient administration will be enabled for both Ntrust-1 and Ntrust-2 trials along with the option to re-dose will be allowed, if needed.
  • 15 Apr 2026 According to a Nkarta Therapeutics Media Release, Rheumatoid arthritis cohort will be added as an indication in Ntrust-2, expanding the study scope to address an additional autoimmune disease with significant unmet need.
  • 10 Nov 2025 According to a Nkarta Therapeutics Media Release, preliminary clinical data are expected to be presented at a medical conference in 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top